Insmed (INSM), whose shares collapsed in August on bad regulatory news, is up 10.7% after...

|By:, SA News Editor

Insmed (INSM), whose shares collapsed in August on bad regulatory news, is up 10.7% after Wedbush starts coverage with an Outperform and $15 PT. The firm thinks the FDA will lift the clinical hold it's placed on studies of Insmed's Arikace drug in late September or early October, and that the drug can address a $300M opportunity.